Replies to post #67577 on Biotech Values

[DewDiligence]

This was one of the best “win-win” biotech deals in 2008, IMHO,
and it’s another example of how Howard Robin is a first-rate CEO.
NKTR needed cash and NVS needed respiratory-device technology
for its QAB-149 program in asthma and COPD; with the demise of
Exubera, NKTR had no further in-house use for the technology.

http://finance.yahoo.com/news/Nektar-Announces-Closing-of-prnews-13942825.html

›Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million

Wednesday December 31, 2008, 9:31 am EST

SAN CARLOS, Calif., Dec. 31 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR ) today announced that it has successfully closed the divestiture of specific Nektar pulmonary delivery assets, technology, and intellectual property to Novartis for $115 million in cash. The transaction was completed on December 31, 2008.

With the closing, Novartis assumes ownership of certain dry powder and liquid pulmonary formulation and manufacturing assets, including capital equipment and manufacturing facility lease obligations. The sale also transferred to Novartis approximately 140 Nektar personnel, as well as certain intellectual property and manufacturing methods, including manufacturing and royalty rights to Novartis' Tobramycin inhalation powder (TIP) program.

Nektar continues to own its Bayer HealthCare-partnered program NKTR-061 (Amikacin Inhale) and royalties from the Ciprofloxacin inhaled powder program (CIP), also partnered with Bayer HealthCare. In addition, Nektar retains its NKTR-063 (inhaled vancomycin) program, as well as all intellectual property specific to inhaled insulin.

JPMorgan acted as exclusive financial advisor to Nektar.

About Nektar

Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its advanced polymer conjugate technology platforms. Nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies. Nektar is also developing a robust pipeline of its own high-value therapeutics that addresses unmet medical needs by leveraging and expanding its technology platforms to improve and enable molecules. For more information on Nektar Therapeutics, please visit http://www.nektar.com.‹